The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1178
March 15, 2004
View Complete Issue         Table of Contents 2019 
Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression
March 15, 2004 (Issue: 1178)
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is mainly used as an antipsychotic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression
Article code: 1178c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.